Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
$588M |
| 2 |
Apple
AAPL
|
$574M |
| 3 |
Illumina
ILMN
|
$398M |
| 4 |
Monster Beverage
MNST
|
$396M |
| 5 |
argenx
ARGX
|
$306M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$600M |
| 2 |
AbbVie
ABBV
|
$323M |
| 3 |
Sherwin-Williams
SHW
|
$309M |
| 4 |
Atlassian
TEAM
|
$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CANO
2651
DELISTED
Cano Health, Inc.
CANO
| $56.6K | ﹤0.01% |
62,148
+39,163
| +170% | +$35.6K |
|
|
AEVA
2652
Aeva Technologies
AEVA
$755M
| $55.1K | ﹤0.01% |
46,298
+24,136
| +109% | +$28.7K |
|
2653
Fulcrum Therapeutics
FULC
$348M
| $54K | ﹤0.01% |
+18,972
| New | +$54K |
|
|
NGM
2654
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $53K | ﹤0.01% |
+13,007
| New | +$53K |
|
2655
Evolv Technologies
EVLV
$1.38B
| $52K | ﹤0.01% |
+16,699
| New | +$52K |
|
2656
Allbirds
BIRD
$51.2M
| $49.7K | ﹤0.01% |
41,587
+21,456
| +107% | +$25.6K |
|
2657
Traeger
COOK
$173M
| $49.6K | ﹤0.01% |
+12,076
| New | +$49.6K |
|
|
NXDR
2658
Nextdoor Holdings
NXDR
$775M
| $49.3K | ﹤0.01% |
+22,961
| New | +$49.3K |
|
|
MMAT
2659
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $49.2K | ﹤0.01% |
120,416
+81,416
| +209% | +$33.3K |
|
2660
Advantage Solutions
ADV
$564M
| $48.9K | ﹤0.01% |
30,763
+18,231
| +145% | +$29K |
|
2661
Latham Group
SWIM
$904M
| $48.2K | ﹤0.01% |
+16,919
| New | +$48.2K |
|
2662
Esperion Therapeutics
ESPR
$458M
| $47.5K | ﹤0.01% |
29,767
+13,669
| +85% | +$21.8K |
|
2663
Tango Therapeutics
TNGX
$737M
| $47.4K | ﹤0.01% |
+11,986
| New | +$47.4K |
|
2664
Precigen
PGEN
$1.43B
| $46.6K | ﹤0.01% |
44,183
+26,235
| +146% | +$27.7K |
|
|
GOEV
2665
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $43.5K | ﹤0.01% |
67,079
+44,990
| +204% | +$29.2K |
|
2666
Organogenesis Holdings
ORGO
$634M
| $41.9K | ﹤0.01% |
19,706
-79,398
| -80% | -$169K |
|
2667
Rackspace Technology
RXT
$309M
| $41.3K | ﹤0.01% |
+22,015
| New | +$41.3K |
|
2668
Holley
HLLY
$481M
| $35.5K | ﹤0.01% |
+12,988
| New | +$35.5K |
|
2669
C4 Therapeutics
CCCC
$175M
| $34.7K | ﹤0.01% |
11,081
-727,548
| -98% | -$2.28M |
|
2670
Outdoor Holding Company Common Stock
POWW
$166M
| $32.9K | ﹤0.01% |
16,698
-28,303
| -63% | -$55.8K |
|
2671
Veru
VERU
$48.2M
| $31.9K | ﹤0.01% |
27,582
+14,834
| +116% | +$17.1K |
|
|
CRGE
2672
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
| $30.5K | ﹤0.01% |
+27,816
| New | +$30.5K |
|
|
TSP
2673
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $29.2K | ﹤0.01% |
+19,767
| New | +$29.2K |
|
|
GTHX
2674
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $28.3K | ﹤0.01% |
+10,566
| New | +$28.3K |
|
|
HYZN
2675
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $27K | ﹤0.01% |
33,097
+16,697
| +102% | +$13.6K |
|